Edgestream Partners’s Denali Therapeutics DNLI Stock Holding History

Edgestream Partners’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-123,819	Closed	-$1.8M	–	985
2025 Q3	$1.8M	Sell	123,819 -219,104	-64%	-$3.15M	0.05%	549
2025 Q2	$4.8M	Buy	+342,923	New	+$4.83M	0.13%	306
2024 Q2	–	Sell	-112,118	Closed	-$2.3M	–	890
2024 Q1	$2.3M	Buy	+112,118	New	+$2.11M	0.11%	304

Other funds holding DNLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Edgestream Partners's DNLI Position: Q4 2025 in Review

Edgestream Partners sold out of Denali Therapeutics (DNLI) in Q4 2025, closing a stake of 123,819 shares — an estimated $1.8M sold.

Edgestream Partners first reported a position in DNLI in Q1 2024 and held it in 3 quarters. The position peaked at $4.8M in Q2 2025. 250 funds tracked by Wall St. Rank hold DNLI as of Q4 2025.

Edgestream Partners reported no remaining Denali Therapeutics position as of Q4 2025 after selling out during the quarter.
Edgestream Partners sold 123,819 Denali Therapeutics shares in Q4 2025, an estimated $1.8M.
Edgestream Partners first reported a position in Denali Therapeutics in Q1 2024 and held it in 3 quarters.
Edgestream Partners's Denali Therapeutics position peaked at $4.8M in Q2 2025.
250 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2025.

Based on Edgestream Partners's 13F filing for Q4 2025, filed 13 Feb 2026.